TopNews

Since long warning have been given regarding how bacteria are cleverly evading the best antibiotics used by us. Such a thing has been seen with MRSA strains and increasingly with C. difficile infections that are common in hospitals. This has indicated that the infections that usually would clear up with a short course of drugs might no longer be controlled. For some infection the case can worsen as there may be no strong enough medications left to fight the bacteria at all.

When strep throat or sinus infections are considered, it is definitely not a welcome scenario. But such a thing could prove fatal for infections after surgery and for cancer patients on chemotherapy, because their immune systems are very weaker.

On Friday, a closely watched start-up that promised to bring revolution in e medical testing, Theranos said that the Food and Drug Administration (FDA) has raised some questions due to which it had temporarily stopped its trademark practice of collection of small blood samples from finger pricks.

As per some reports, the privately held Theranos has been valued at over $9 billion, nearly similar to the laboratory giants Quest and LabCorp. That is based on purported ability of Theranos to perform a lot of medical tests with the help of only drops of blood from a finger, and not from the conventional huge vials taken from the crook of the arm.

In an announcement Shire plc said that the company has been asked by the US Food and Drug Administration (FDA) for an additional clinical study in a complete response letter (CRL) to its new drug application for lifitegrast. The drug is used for the signs and symptoms of dry eye disease in adults.

Recently, the company has completed a Phase 3 study of lifitegrast, OPUS-3, that will likely be the basis of response of Shire to the CRL. The FDA has also asked for more information about the product quality, which Shire is going to address in the CRL response.

Before the end of this year, the Topline results of OPUS-3 are expected. It they come positive then the company will submit the data to the FDA as part of a resubmission in the first quarter of 2016.

It is being said that worst phase of Ebola outbreak has passed away, but then also, the virus keeps on reappearing in survivors, new patients and press. One of the examples is Pauline Cafferkey, a Scottish nurse, who has served in Sierra Leone when outbreak was on in West Africa.

Nine months after her initial infection and recovery, she was once again having the Ebola virus and now, she is taking treatment at London’s Royal Free Hospital. In the last 24 hours, the Ebola virus has been diagnosed in two people in Guinea.

Europe's climate chief said in a statement that the European Union will push up for an UN deal to cope up with global warming problems that have been affecting the world and will check the outcome for every five years.

Miguel Arias Canete, Climate and Energy Commissioner, said that any deal that will be signed in Paris agreement should have an agenda i.e. active increase of ambition over time to cut further emissions.

Arias Canete said, “We do not want the Paris agreement with commitments ending in 2030 because the Paris agreement cannot be an agreement that starts in 2020 or 2021 and finishes in 2030, like the Kyoto Protocol, which finishes in 2020”.

Caffeine is not produced by only plants coffee and cocoa. The drug is present in the pollen of some flowers. Some researchers suggested that caffeine could be beneficial to bees, but a latest research has added doubt to the theory.

As per previous research, caffeine makes the bee memory better, which not only allows them to discover the most optimal plants for pollination but also enables them to remember their paths so that they can remember their way in a better way to the right flower every time.